Henan Meitaibao Biopharmaceutical

Henan Meitaibao Biopharmaceutical is a Chinese biopharmaceutical company focused on the discovery, development, and commercialization of innovative Class 1 drugs. Founded in 2015 by Dr. Jinfa Du, the inventor of the blockbuster HCV drug Sofosbuvir, the company targets high-unmet-need areas including oncology, infectious diseases, and cardiovascular conditions. Its pipeline features several promising small molecule candidates, such as the third-generation EGFR inhibitor doxitinib for lung cancer and the long-acting antiviral CL-197 for HIV. Meitaibao operates in close strategic partnership with Genuine Biotech and Henan Normal University, contributing significantly to the clinical success of the approved antiviral Azvudine.